| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2015-09-01 | Subgam®VF | primary immune deficiency disorders, common variable immunodeficiency, X-linked agammaglobulinaemia, hyperimmunoglobulin M syndrome | 3 | Bio Products Laboratory (UK) | Immunological diseases |
| 2015-09-01 | VM202 | chronic non-healing ischemic diabetic foot ulcers | 3 | ViroMed (Republic of Korea) | Cardiovascular diseases - Metabolic diseases |
| 2015-09-01 | cetux-CAR T cells, nimo-CAR T cells | preclinical | Ziopharm Oncology (USA - MA) | Cancer - Oncology | |
| 2015-09-01 | HS-110 (viagenpumatucel-L) and nivolumab | non-small cell lung cancer (NSCLC) | 1b | Heat Biologics (USA - NC) | Cancer - Oncology |
| 2015-08-31 | CicloMulsion® cremophor-free IV cyclosporine formulation | myocardial infarction | 3 | NeuroVive Pharmaceutical (Sweden) Hospices Civils de Lyon (France) | Cardiovascular diseases |
| 2015-08-31 | Brilinta® (ticagrelor) | secondary prevention of atherothrombotic events in patients who had experienced a heart attack | AstraZeneca (UK) | Cardiovascular diseases | |
| 2015-08-31 | Dysport® (abobotulinumtoxin A ) | upper limb spasticity | 3 | Ipsen (France) | Neurological diseases - CNS diseases |
| 2015-08-31 | finerenone (BAY 94-8862) | diabetic kidney disease | 3 | Bayer Healthcare (Germany) | Kidney diseases - Metabolic diseases - Renal diseases |
| 2015-08-31 | PINTA 745 | patients with end stage renal disease who require maintenance hemodialysis and have protein energy wasting | 1-2 | Atara Biotherapeutics (USA - CA) | Kidney diseases - Renal diseases |
| 2015-08-31 | BNC101 | metastatic colon cancer, metastatic pancreatic cancer | 1 | Bionomics (Australia) | Cancer - Oncology |
| 2015-08-30 | Reolysin® (pelareorep - human reovirus type 3 Dearing strain) | previously treated advanced or metastatic non-small cell lung cancer | 2 | Oncolytics Biotech (Canada) NCIC Clinical Trials Group (Canada) | Cancer - Oncology |
| 2015-08-27 | durvalumab (MEDI4736) and tremelimumab or AZD9150 | diffuse large B-cell lymphoma (DLBCL) | 1 | AstraZeneca (UK) | Cancer - Oncology |
| 2015-08-27 | daratumumab | relapsed/refractory multiple myeloma | 1-2 | Genmab (Denmark) | Cancer - Oncology |
| 2015-08-27 | Opsumit® (macitentan) | pulmonary arterial hypertension (PAH) | Actelion (Switzerland) | Rare diseases - Cardiovascular diseases - Autoimmune diseases | |
| 2015-08-27 | Zydelig® (idelalisib) and ofatumumab | previously-treated patients with chronic lymphocytic leukemia (CLL) | 3 | Gilead (USA - CA) | Cancer - Oncology |
| 2015-08-26 | combination of ambrisentan and tadalafil | pulmonary arterial hypertension (PAH) | 3 | Gilead (USA - CA) GSK (UK) | Rare diseases - Cardiovascular diseases |
| 2015-08-26 | Victoza® (liraglutide) | type 1 diabetes | 3 | Novo Nordisk (Denmark) | Metabolic diseases |
| 2015-08-26 | semaglutide | type 2 diabetes | 3a | Novo Nordisk (Denmark) | Metabolic diseases |
| 2015-08-26 | durvalumab (MEDI4736) and tremelimumab | non-small cell lung cancer (NSCLC) | 3 | AstraZeneca (UK) | Cancer - Oncology |
| 2015-08-26 | Ibrance® (palbociclib) | breast cancer | 3 | Alliance Foundation Trials (USA) Pfizer (USA - NY) | Cancer - Oncology |
